17. Ma CX, Bose R, Ellis MJ. Prognostic and predictive
biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer. Adv Exp Med
Biol 2016;882:125–54.
18. Eiermann W, Paepke S, Appfelstaedt J, et al.
Preoperative treatment of postmenopausal
breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol
2001;12:1527–32.
19. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant
treatment of postmenopausal breast cancer with
anastrozole, tamoxifen, or both in combination: the
Immediate Preoperative Anas-trozole, Tamoxifen,
or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol
2005;23:5108–16.
20. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for
estrogen receptor-positive breast cancer based on
postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380– 8.
21. Paik S, Shak S, Tang G, et al. A multigene assay to
predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–26.
22. Fisher B, Jeong JH, Bryant J, et al. Treatment of
lymph-node-negative, oestrogen-receptor-positive
breast cancer: long-term findings from National
Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364:858–68.
23. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of
breast cancer death among lymph node-negative
patients. Breast Cancer Res 2006;8:R25.
24. Albain KS, Barlow WE, Shak S, et al. Prognostic and
predictive value of the 21-gene recurrence score
assay in postmenopausal women with node-positive,
oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised
trial. Lancet Oncol 2010;11:55–65.
25. Dowsett M, Cuzick J, Wale C, et al. Prediction of
risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive
postmenopausal patients with breast cancer treated
with anastrozole or tamoxifen: a TransATAC study. J
Clin Oncol 2010;28:1829–34.
26. Paik S, Shak S, Tang G, et al. Expression of the 21
genes in the recurrence score assay and tamoxifen
clinical benefit in the NSABP study B- 14 of node
negative, estrogen receptor positive breast cancer. J
Clin Oncol 2005;23: suppl:510.
27. Paik S, Tang G, Shak S, et al. Gene expression and
benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J
Clin Oncol 2006;24:3726–34.
28. Sparano JA, Gray RJ, Makower DF, et al. Prospective
validation of a 21-gene expression assay in breast
cancer. N Engl J Med 2015;373:2005– 14.
29. Parker JS, Mullins M, Cheang MC, et al. Supervised
risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol 2009;27:1160– 7.
30. Dowsett M, Sestak I, Lopez-Knowles E, et al.
Comparison of PAM50 risk of recurrence score
with oncotype DX and IHC4 for predicting risk of
distant recurrence after endocrine therapy. J Clin
Oncol 2013;31:2783–90.
31. Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer
patients with limited clinicopathological risk: using
the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG- 8 trial treated
with adjuvant endocrine therapy alone. Ann Oncol
2014;25:339–45.
32. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med 2002;347:1999–2009.
33. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast
Cancer Res Treat 2010;120:655–61.
34. Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-gene
signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717–29.
35. Sapino A, Roepman P, Linn SC, et al. MammaPrint
molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J Mol Diagn 2014;16:190– 7.
36. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immuno-histochemistry and clinical prognostic factors in
tamoxifen-treated estrogen receptor-positive breast
cancer. Clin Cancer Res 2010;16:5222– 32.
37. Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive,
HER2-negative breast cancer adds independent
information to conventional clinical risk factors.
Clin Cancer Res 2011;17:6012–20.
38. Jerevall PL, Ma XJ, Li H, et al. Prognostic utility
of HOXB13:IL17BR and molecular grade index
in early-stage breast cancer patients from the
Stockholm trial. Br J Cancer 2011;104:1762– 9.
39. Zhang Y, Schnabel CA, Schroeder BE, et al.
Breast cancer index identifies early-stage estrogen
receptor-positive breast cancer patients at risk for
early- and late-distant recurrence. Clin Cancer Res
2013;19:4196–205.
40. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late
distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison
